Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls


USTAALIOGLU B. O. , BILICI A., ERCAN S., ORCUN A., SEKER M., OZKAN A., ...More

CLINICAL & TRANSLATIONAL ONCOLOGY, vol.14, no.5, pp.356-361, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 14 Issue: 5
  • Publication Date: 2012
  • Doi Number: 10.1007/s12094-012-0808-0
  • Title of Journal : CLINICAL & TRANSLATIONAL ONCOLOGY
  • Page Numbers: pp.356-361

Abstract

M30 and M65 are derivatives of cytokeratin 18 and released from the epithelial cell during cell death. These markers can be used to evaluate prognosis and chemotherapy response in several tumours. We evaluated serum M30 and M65 values in patients with advanced non-small-cell lung cancer (NSCLC) compared with those in a healthy group.